Mabwell(SH:688062) Zheng Quan Shi Bao Wang·2025-09-17 09:49Core Insights - Maiwei Bio has signed an exclusive licensing agreement and a preferred stock purchase agreement with Kalexo Bio, Inc. regarding the 2MW7141 project, allowing Kalexo exclusive global rights for development, production, and commercialization of the licensed product [1] - The agreements could yield up to $1 billion in upfront and milestone payments for Maiwei Bio, including an initial non-refundable payment of $12 million in cash and double-digit preferred stock in Kalexo [1] - 2MW7141 is a preclinical dual-target small nucleic acid drug aimed at lipid regulation in patients with dyslipidemia and prevention of high-risk cardiovascular events, showing strong and lasting inhibitory effects on target genes with low off-target risk [1] Company Development - The successful advancement of the 2MW7141 project validates the effectiveness of Maiwei Bio's self-developed dual/multi-target small nucleic acid drug research platform, which integrates artificial intelligence and high-throughput automated screening, significantly enhancing research efficiency [2] - The platform's modular development advantages may extend to more therapeutic areas, strengthening Maiwei Bio's strategic positioning in age-related diseases [2] Partner Company Overview - Kalexo is an innovative pharmaceutical company established by Aditum Bio Fund3, L.P., focusing on biopharmaceutical innovation through venture capital and incubation, co-founded by former Novartis executives Joe Jimenez and Mark Fishman in 2019 [2] - Aditum Bio aims to accelerate the transition of new drugs from early research to clinical stages by selecting promising, unmet medical needs in innovative drugs, therapies, or technologies with clear biological mechanisms and high clinical value [2]